CD40LG and B-cell chronic lymphocytic leukemia: These data were confirmed in ibrutinib-treated CLL cells (n = 7), where the addition of idelalisib to CLL cells collected at day 30 on ibrutinib was able to completely antagonize anti-IgM–induced VLA-4 activation (Fig. 3 D).